

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.2D6APPLICATION NO.
10/741,929SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Clarence N. Ahlem, et alFILING DATE
December 19, 2003GROUP
1617

(USE SEVERAL SHEETS IF NECESSARY)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	4,096,254	06-20-78	Benson et al			

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	DOCUMENT PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	Cunningham, G.R. et al, Steroid structural requirements for high affinity binding to human sex steroid binding protein (SBP), <i>Steroids</i> 38(3):243-262 1981
	Ederveen, A.G., et al, Tibolone, a steroid with a tissue-specific hormonal profile, completely prevents ovariectomy-induced bone loss in sexually mature rats, <i>J Bone Miner Res.</i> , 14 (11):1963-70 1999
	Tedesco, R., Katzenellenbogen, J. A. and Napolitano, E. 7 α ,11 β -Disubstituted estrogens: Probes for the shape of the ligand binding pocket in the estrogen receptor. <i>Bioorg. Med. Chem. Lett.</i> , 7:2919-2924 1997
	Tobias, J.H., et al., 5 α -dihydrotestosterone partially restores cancellous bone volume in osteopenic ovariectomized rats, <i>Am. J. Physiol. Endocrinol. Metab.</i> 267:E853-E859 1994

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.